GAPP Induction and Concurrent Chemoradiotherapy for High-risk Locoregionally Advanced NPC.
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE3
Clinical Trials Related to Anlotinib
Related studies linked through entity extraction aliases.
A Study of Benmelstobart, Anlotinib, Chemotherapy and Thoracic Radiotherapy for People With Extensive-stage Small Cell Lung Cancer
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE2
Benmelstobart Plus Anlotinib, Chemotherapy and Thoracic Radiation for Limited-Stage Small Cell Lung Cancer
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE2
Benmelstobart Plus Anlotinib Combined With SBRT for Patients With Hepatocellular Carcinoma Failing First-Line Targeted Therapy
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE2
SBRT Plus Anlotinib and Bimepolizumab in Locally Advanced or Metastatic Renal Cell Carcinoma
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE2
Anlotinib Plus Whole-Brain Radiotherapy for Brain Metastases in SCLC Patients.
- Status
- RECRUITING
- Phase
- PHASE3
Sacituzumab Tirumotecan Plus Anlotinib in Previously Treated ES-SCLC
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE2
Prospective, Single-arm, Phase II Clinical Study of Irinotecan Hydrochloride Liposome Injection Combined With Platinum and Immune Checkpoint Inhibitors Combined With Anlotinib for the Maintenance of Extensive Small Cell Lung Cancer After First-line Induction
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE2
A Phase II Clinical Study Evaluating Entinostat With or Without Anlotinib + Fulvestrant for the Treatment of Hormone Receptor (HR) -Positive, Human Epidermal Growth Factor Receptor-2 (HER-2) -Negative Advanced Breast Cancer That Relapsed or Progressed After Endocrine Therapy
- Status
- RECRUITING
- Phase
- PHASE2
Chidamide in Combination With Toripalimab and Anlotinib in Recurrent/Metastatic Nasopharyngeal Carcinoma.
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE1/PHASE2
Open-Label, Biomarker-Integrated Umbrella Trial for First-Line Treatment of Extensive-stage Small Cell Lung Cancer
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE2
Radiotherapy Plus Anlotinib in LA-NSCLC Intolerable to cCRT
- Status
- RECRUITING
- Phase
- PHASE2
Sequential Anti-Angiogenic Therapy After Immunotherapy in Advanced Biliary Tract Cancer
- Status
- RECRUITING
- Phase
- PHASE2
Genotype-Driven Neoadjuvant Therapy for Locally Advanced Thyroid Cancer: A Real-World Cohort Study
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE4
Safety and Efficacy of Anlotinib in the Treatment of Recurrent Craniopharyngioma
- Status
- RECRUITING
- Phase
- PHASE1/PHASE2
Prospective, Single-arm, Phase II Clinical Study of Irinotecan Hydrochloride Liposome Injection Combined With Platinum and Immune Checkpoint Inhibitors Combined With Anlotinib for the Maintenance of Extensive Small Cell Lung Cancer After First-line Induction
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE4
Benmelstobart, Anlotinib and Chemotherapy as First-line Treatment for Extensive-stage Small-cell Lung Cancer
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE4
GAPP Induction and Concurrent Chemoradiotherapy Followed by Toripalimab Maintenance for Nasopharyngeal Carcinoma.
- Status
- RECRUITING
- Phase
- PHASE2
A Prospective, Single-arm Clinical Study of Liposomal Mitoxantrone Combination Regimen in the Treatment of Relapsed and Refractory Solid Tumors in Children, Adolescents and Young Adults
- Status
- RECRUITING
- Phase
- PHASE2
Precision Medicine Trial Based on Molecular Matching Therapy for Patients With Standard Treatment Exhaustion
- Status
- RECRUITING
- Phase
- PHASE2